Skeletal metastasis: treatments, mouse models, and the Wnt signaling.
- Author:
Kenneth C VALKENBURG
1
;
Matthew R STEENSMA
;
Bart O WILLIAMS
;
Zhendong ZHONG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Bone Neoplasms; drug therapy; metabolism; radiotherapy; secondary; surgery; Breast Neoplasms; metabolism; pathology; Disease Models, Animal; Drug Delivery Systems; Female; Humans; Lung Neoplasms; metabolism; pathology; Male; Mice; Prostatic Neoplasms; metabolism; pathology; Wnt Proteins; metabolism; Wnt Signaling Pathway; beta Catenin; metabolism
- From:Chinese Journal of Cancer 2013;32(7):380-396
- CountryChina
- Language:English
- Abstract: Skeletal metastases result in significant morbidity and mortality. This is particularly true of cancers with a strong predilection for the bone, such as breast, prostate, and lung cancers. There is currently no reliable cure for skeletal metastasis, and palliative therapy options are limited. The Wnt signaling pathway has been found to play an integral role in the process of skeletal metastasis and may be an important clinical target. Several experimental models of skeletal metastasis have been used to find new biomarkers and test new treatments. In this review, we discuss pathologic process of bone metastasis, the roles of the Wnt signaling, and the available experimental models and treatments.
